Sphenopalatine Ganglion Block in Septorhinoplasty

The Effect of Sphenopalatine Ganglion Block on Intraoperative Remifentanil Consumption and Postoperative Pain in Septorhinoplasty Surgery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06157970

Enrollment

Registered

2023-12-06

Start date

2023-06-07

Completion date

2023-08-21

Last updated

2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Rhinoplasty

Brief summary

Septorhinoplasty is a widely performed surgery that aims to correct both functional and aesthetic problems of the nose. Despite its expected clinical benefits, septorhinoplasty surgery causes postoperative pain, which affects the patient's functional recovery and satisfaction. Opioids, Non-steroidal anti-inflammatory drugs (NSAII), acetaminophen and local anesthetics are used in peroperative pain management in septorhinoplasty. Sphenopalatine ganglion block (SPGB), which has been recently described and has different application areas, is a regional analgesia technique that has been investigated for this purpose. Although there are studies on postoperative pain in septorhinoplasty surgeries, there are not enough studies on its effects on intraoperative pain. This study may have positive effects on appropriate pain management, patient comfort and surgical outcomes as multimodal analgesia management in septorhinoplasty surgeries, and may make significant contributions to evidence-based practices.

Interventions

PROCEDURESphenopalatine Ganglion Block

For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Undergoing septorhinoplasty surgery * Ages between 18-65 * ASA (American Society of Anesthesiologists) score I-II

Exclusion criteria

* Unavailable postoperative pain scores and analgesic use in the hospital registry system * Local anesthetic drug allergy and toxicity * Advanced organ failure * Mental retardation Patients who are pregnant

Design outcomes

Primary

Measure	Time frame	Description
remifentanil consumption	2 hours	microgram

Secondary

Measure	Time frame	Description
Numerical Rating Scale	15 minute, 30 minute, 1hour, 2 hour, 4 hour, 8 hour,16 hour, 24 hour	Minimum values=1 and Maximum value=10. Highest values are worse outcome.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026